Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, noviembre 18
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Zenas BioPharma Inc
ZBIO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$27.75
-0.18
-0.64%
al cierre: Nov 17, 4:00 PM EST
$29.33
1.58
5.69%
After hour: 4:33 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Zenas BioPharma Financials
Zenas BioPharma (ZBIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Zenas BioPharma Q3 EPS $(1.65) Misses $(1.33) Estimate, Sales $10.000M
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.33) by 24.06 percent. This is a 35.25 percent decrease over losses of $(1.22) per share
Benzinga Newsdesk
PRO
Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.08) by 63.89 percent. This is a 41.6 percent decrease over losses of $(1.25) per share from
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Zenas BioPharma Q1 EPS $(1.46) Misses $(1.17) Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.17) by 24.79 percent. This is a 82.5 percent decrease over losses of $(0.80) per share from
Benzinga Newsdesk
PRO
Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(4.54) per share. This is a 260.32 percent decrease over losses of $(1.26) per share from the same period last year.
Benzinga Newsdesk
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
Avi Kapoor